Juan Cristobal Sanchez
Overview
Explore the profile of Juan Cristobal Sanchez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ospina-Serrano A, Maximiano C, Cantos B, Torrente M, Mendez M, Sanchez J, et al.
Clin Transl Oncol
. 2023 Nov;
26(5):1147-1156.
PMID: 37917247
Background: Sexual dysfunction (SD) associated with oncological treatment is a common and understudied disorder. Our aim was to characterize SD in a cohort of Spanish patients. Methods: Analytic observational study...
2.
Nunez-Garcia B, Clemente M, Sanchez J, Royuela A, Cantos Sanchez de Ibarguen B, Mendez M, et al.
Hematol Oncol
. 2023 Mar;
41(3):407-414.
PMID: 36934306
The high cure rates of Hodgkin lymphoma (HL) make this oncological disease among those with the greatest number of long-term survivors. This single-institution study including 383 HL patients with up...
3.
Torrente M, Blanco M, Franco F, Garitaonaindia Y, Calvo V, Collazo-Lorduy A, et al.
Front Cardiovasc Med
. 2022 Dec;
9:1062858.
PMID: 36531707
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, despite their excellent therapeutic effect, these medications typically result in a broad spectrum of toxicity reactions. Immune-related cardiotoxicity is uncommon...
4.
Torrente M, Sousa P, Hernandez R, Blanco M, Calvo V, Collazo A, et al.
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36011034
Background: Artificial intelligence (AI) has contributed substantially in recent years to the resolution of different biomedical problems, including cancer. However, AI tools with significant and widespread impact in oncology remain...
5.
Sanchez J, Iglesias P
Endocrinol Diabetes Nutr (Engl Ed)
. 2022 May;
69(5):313-315.
PMID: 35624064
No abstract available.
6.
Iglesias P, Sanchez J, Diez J
Pituitary
. 2021 Mar;
24(4):630-643.
PMID: 33761049
Immunotherapy with immune checkpoint inhibitor (ICI) monoclonal antibodies has shown to be an effective therapeutic alternative in several malignant tumors. However, adverse effects related to an activation of the immune...
7.
Provencio M, Perez-Barrios C, Barquin M, Calvo V, Franco F, Sanchez E, et al.
Clin Chem Lab Med
. 2019 Aug;
58(2):306-313.
PMID: 31469650
Background Non-small cell lung cancer (NSCLC) patients benefit from targeted therapies both in first- and second-line treatment. Nevertheless, molecular profiling of lung cancer tumors after first disease progression is seldom...
8.
Cruz-Bermudez A, Laza-Briviesca R, Vicente-Blanco R, Garcia-Grande A, Coronado M, Laine-Menendez S, et al.
Free Radic Biol Med
. 2018 Nov;
130:163-173.
PMID: 30391585
Lung cancer is a major public health problem due to its high incidence and mortality rate. The altered metabolism in lung cancer is key for the diagnosis and has implications...
9.
Perez-Callejo D, Zurutuza L, Royuela A, Torrente M, Nunez B, Calvo V, et al.
Oncotarget
. 2018 Mar;
9(14):11638-11645.
PMID: 29545926
Background: Hodgkin lymphoma (HL) is the paradigm of curable disease. This study analyzed the overall survival (OS) of patients with HL and compared their survival between decades and with the...